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Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by fibrillar
cytoplasmic aggregates of α-synuclein (i.e., Lewy bodies) and the associated loss of dopaminergic
cells in the substantia nigra. Mutations in genes such as α-synuclein (SNCA) account for only 10% of
PD occurrences. Exposure to environmental toxicants including pesticides and metals (e.g., paraquat
(PQ) and manganese (Mn)) is also recognized as an important PD risk factor. Thus, aging, genetic
alterations, and environmental factors all contribute to the etiology of PD. In fact, both genetic and
environmental factors are thought to interact in the promotion of idiopathic PD, but the mechanisms
involved are still unclear. In this study, we summarize our findings to date regarding the toxic
synergistic effect between α-synuclein and paraquat treatment. We identified an essential role for
central carbon (glucose) metabolism in dopaminergic cell death induced by paraquat treatment that is
enhanced by the overexpression of α-synuclein. PQ “hijacks” the pentose phosphate pathway (PPP)
to increase NADPH reducing equivalents and stimulate paraquat redox cycling, oxidative stress, and
cell death. PQ also stimulated an increase in glucose uptake, the translocation of glucose transporters
to the plasma membrane, and AMP-activated protein kinase (AMPK) activation. The overexpression
of α-synuclein further stimulated an increase in glucose uptake and AMPK activity, but impaired
glucose metabolism, likely directing additional carbon to the PPP to supply paraquat redox cycling.
Keywords: Parkinson’s Disease; genetics; toxin synergy; molecular mechanisms; NMR; mass spectrometry
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1. Introduction
1.1. Parkinson’s Disease Overview
Parkinson’s disease (PD) affects over one million individuals in the United States and more than
10 million people worldwide [1]. PD is a chronic progressive neurodegenerative disorder that leads
to shaking (tremors) and difficulty with walking, movement, and coordination. Currently, there is
no cure for PD or drug to stop the progression of the disease, but there are treatments to manage
symptoms [2]. PD is associated with the loss of dopaminergic neurons from the substantia nigra pars
compacta within the midbrain (Figure 1a) [3,4]. The death of these dopaminergic neurons leads to
a deficiency of dopamine in the caudate and putamen (“striatum”), which results in an observed
loss of muscle control. In addition to neuron loss, PD is also characterized by the presence of Lewy
bodies—protein aggregates within neurons [5]. The exact cause of PD is currently unknown, but age is
an important risk factor [6]. Individuals over the age of 60 are twice as likely to develop PD relative to
the general population. Only about 10% of PD cases have a family history of the disease, and, to date,
18 genetic mutations (PARK1, PARK2, etc.) have been putatively linked to PD [7,8]. Genetic alterations
in α-synuclein [9,10], Parkin [11,12], DJ-1 [13], PINK1 [11], and LRRK2 [14] have been associated
with approximately 3 to 5% of PD. Environmental factors have also been linked to an increase in
the incidence of PD or risk for developing PD [15]. In fact, sporadic or idiopathic PD is linked to
genetic alterations and occupational or environmental factors. Exposure to pesticides, heavy metals,
infectious agents, industrialization, and/or dietary factors has been associated with an increased
occurrence of PD. Recent studies have demonstrated that environmental exposures modify DNA
methylation patterns, chromatin structure, and non-coding RNA signaling (epigenetics), which might
contribute to the individual’s susceptibility to developing PD. Epigenetic patterns defined during aging
and development can be altered by environmental exposures [16–18]. Paraquat induces epigenetic
changes by promoting histone acetylation [19] and, conversely, paraquat toxicity has been reported
to be enhanced by inhibition of DNA methyltransferases [20]. Thus, PD appears to be multifactorial
where a combination of age, genetics, and environmental factors contributes to disease development
(Figure 1b) [21].
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Figure 1. Parkinson’s disease results from dopaminergic neuron cell death in the substantia nigra: (a) 
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fluorodopa PET. The signal from striatum in a healthy control subject, a patient with symptomatic 
Parkinson’s disease and a twin who was asymptomatic at the time of scan but who subsequently 
developed the disease. Reproduced with permission from [3]. (b) Schematic of the multiple factors 
that contribute to the development of Parkinson’s disease. Both aging and environmental factors modify 
epigenetic patterns, which may also enhance an individual’s likelihood of developing PD.  
1.2. PD and Environmental Risk Factors 
The largest epidemiology study of PD in the USA identified a number of environmental factors 
correlated with an increased incidence of PD [22]. Specifically, PD was found to be more common in 
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Figure 1. Parkinson’s disease results from dopaminergic neuron cell death in the substantia nigra:
(a) In vivo imaging of dopaminergic activity in the Parkinsonian basal ganglia shown by [18F]
fluorodopa PET. The signal from striatum in a healthy control subject, a patient with symptomatic
Parkinson’s disease and a twin who was asymptomatic at the time of scan but who subsequently
developed the disease. Reproduced with permission from [3]. (b) Schematic of the multiple factors that
contribute to the development of Parkinson’s disease. Both aging and environmental factors modify
epigenetic patterns, which may also enhance an individual’s likelihood of developing PD.
1.2. PD and Environmental Risk Factors
The largest epidemiology study of PD in the USA identified a number of environmental factors
correlated with an increased incidence of PD [22]. Specifically, PD was found to be more common
in the Midwest and the Northeast. In fact, the state of Nebraska was observed to have the highest
prevalence of PD in the world (Table 1). Again, this is consistent with areas associated with agriculture
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and metal processing having high rates of PD. Thus, prolonged exposure to herbicides or insecticides
from farming or metals from industry likely contributes to PD. Consequently, paraquat (herbicide),
rotenone (insecticide), 6-hydroxydopamine (6-OHDA, neurotoxin), 1-methyl-4-phenylpyridinium
(MPP+, herbicide), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, prodrug), and manganese
have all been shown to induce PD-like symptoms. These compounds are routinely and interchangeably
used to induce dopaminergic neuron cell death and as chemical mimics of PD in animal models.
MPTP was discovered as a contaminant in illicit opioid synthesis, and acts as a prodrug that is
converted to MPP+ in the brain and is selectively taken up by dopaminergic cells [23,24]. MPP+ inhibits
mitochondrial respiratory complex I of the electron transport chain and interferes with oxidative
phosphorylation in the mitochondria [25,26]. Paraquat has a structure similar to MPTP, but is a poor
inhibitor of complex I. Instead, paraquat toxicity has been primarily attributed to its redox cycling that
generates reactive oxygen species (ROS). Paraquat is reported to induce dopaminergic degeneration
in vivo, which is one of the pathological hallmarks of PD, but contradictory results exist as well. While
some environmental toxicants linked to PD such as PQ have been demonstrated to have a limited
capacity to diffuse across the blood–brain barrier (BBB) [27,28], a significant increase in the permeability
of the BBB in the postcommissural putamen of PD patients has been reported [29] and breakdown of
the BBB has been shown to occur during aging [30]. Interestingly, α-synuclein impairs tight junction
protein expression [30]. These findings again suggest the likelihood that neurodegeneration linked to
environmental exposure is a consequence of genetics and or aging converging to promote dopaminergic
cell loss.
The chemical similarity between paraquat and MPTP initiated an investigation into an agricultural
link with PD. Consequently, a correlation between paraquat agricultural usage and PD rates has been
observed. The naturally occurring insecticide rotenone also inhibits complex I, which leads to energy
failure and cell death [31,32]. Similarly, 6-OHDA has been proposed to induce dopaminergic neuron
cell death by producing pro-oxidant capacity and selective uptake via dopamine transporters [23,33,34].
Table 1. Prevalence of PD in Nebraska [35].
Age (Years)
Nebraska PD Prevalence
60–70 70–80 80+(Rates per 100,000)
Men 406 1794 4248
Women 298 991 2069
Regardless of the environmental toxin, there appears to be a common mechanism that leads
to dopaminergic neuron cell death. Neurons have a very high energy demand and high glucose
usage. Consequently, alterations in energy metabolism have been reported in early PD. Specifically,
environmental toxins alter redox homeostasis, energy metabolism, and central carbon metabolism.
Environmental toxins appear to increase ROS either through a direct redox cycling or indirectly by
inhibiting the electron transport chain. Consequently, this leads to dysfunctional mitochondria and cell
death. Thus, toxin-induced alterations in metabolic pathways important to central carbon metabolism,
energy metabolism and redox homeostasis present a clear role for metabolomics in investigating PD.
1.3. Lewy Bodies and α-Synuclein
A hallmark of PD is the formation of intracellular protein aggregates or Lewy bodies in the
dopaminergic neurons within the substantia nigra (Figure 2a) [36]. Lewy bodies are found in the
cytoplasm as single or multiple spherical masses consisting of a dense protein core surrounded by a
pale halo. Lewy bodies have a filamentous structure and contain over 70 different biological molecules
falling within 10 distinct classes. α-Synuclein is a major component of Lewy bodies and forms the fibrils
(Figure 2b) [37,38]. In addition to α-synuclein fibrils, other components of Lewy bodies correspond to
proteins involved in: (i) α-synuclein binding; (ii) synphilin-1-binding; (iii) ubiquitin-proteasome system;
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(iv) cellular responses; (v) phosphorylation and signal transduction; (vi) cytoskeleton; and (vii) the cell
cycle. Importantly, Lewy bodies are correlated with neuronal loss and cognitive impairment, which
suggests that neurons that contain Lewy bodies are dying. However, there is no evidence that Lewy
bodies are the actual cause of cell death. In fact, Lewy bodies may be a cytoprotective mechanism in
PD, while α-synuclein protofibrils might be cytotoxic agents. Lewy bodies may function to sequester
and degrade the α-synuclein fibrils.
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Figure 2. (a) Substantia nigra from patients with Parkinson’s disease (from the MRC Cambridge
Brain Bank) immunostained for α-synuclein. (Top) Two pigmented nerve cells, each containing an
α-synuclein-positive Lewy body (long arrows). Lewy neurites (short arrows) are also immunopositive.
Scale bar, 20 µm. (Bottom Left) A pigmented nerve cell with two α-synuclein-positive Lewy bodies.
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Reproduced with permission from [38]. (b) α-synuclein (α-syn) aggregation can take place either
in the cytoplasm or in association with the cellular membrane. In the cytosol, unfolded monomers
interact to form initially unstable dimers, which grow slowly to generate oligomers of varying
morphologies—including transient spherical and ring-like oligomers—that eventually convert to
fibrils. The α-syn oligomers are in equilibrium with monomers and convert to fibrils by monomer
addition via a nucleated polymerization mechanism. The accumulation of these amyloid fibrils leads
to the formation of intracellular inclusions called Lewy bodies. Membrane-bound monomeric α-syn
adopts a predomina tly α-helical confirmation, but at high concentrations the protei undergoes a
conformational change either before or coincident with its olig merization to form membrane-b und
β-sheet-rich structures that self-associate to form oligomers, including trans-membran amyloid pores
(the formation of which may involve several intermediates) and fibrils. Note that the ring-lik cytos lic
oligomers may also associate with the m mbrane a d form trans-mem ane pores. During α-syn
fibrill genesis and aggregation, the intermediate species (oligomers and a yloid fibrils) are highly
toxic, affectin mitocho rial functi , endoplas ic reticulum–Golg trafficking, protein egradation
and/or synaptic transmission, and these intracellular effects are thought to induce neurodegeneratio .
The transmembrane pores disrupt embrane integrity as well as intrac llular calcium homeostasis
and signali g, and may also contribute to neuronal toxicity. Interestingly, α-syn oligomers and fibrils,
as well as th monomers, can be tr sferred between cells and induce disease spreadi to other
brain r gions. Spreading mechanisms are ultiple and can occur via endocytosis, direct penetration,
trans-synaptic transmission, r membrane receptors. Once inside the host cells, α-syn aggregates can
nucleate agg egation d propagate via the mechanisms described above. Reproduce with permission
from [39].
α-Synuclein is a 140-amino-acid (14.5 kDa) protein of unknown function that is a natively
unstructured monomer (Figure 3a) [39,40]. However, there has been some progress in revealing a role
for α-synuclein in vesicle trafficking, synaptic vesicles endocytosis, and chaperoning of the SNARE
complex assembly [41–43]. The protein consists of three distinct domains: (i) an amphipathic lysine-rich
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N-terminus (1–60) that interacts with membranes and forms an α-helix; (ii) an acidic disordered
C-terminus (96–140) that is postulated to regulate nuclear localization and is involved in interactions
with metals, small molecules and other proteins; and (iii) a hydrophobic central region (61–95), which
is critical for protein aggregation and is commonly referred to as the non-amyloid-β component of
AD amyloid plaques (NAC) (Figure 3b). α-Synuclein is an abundant neuronal protein (~1% of cytosol
proteins) that is expressed throughout the brain with particularly high levels in the substantia nigra.
α-Synuclein is primarily located in the presynaptic terminal of neurons. Thus, the protein may play
a role in regulating the release of dopamine or the supply of synaptic vesicles. Genetic mutations in
α-synuclein (SNCA) [9,10] or overexpression due to multiplication of SNCA [44] have been associated
with familial and sporadic PD (Figure 3b). Oligomerization of α-synuclein and the resulting fibril
formation is central to the pathogenesis of PD (Figure 2b). α-Synuclein aggregates have been shown to
bind lipid membranes, to form pore-like structures, and to increase membrane permeability [45–48].
The resulting α-synuclein aggregates cause neuroinflammation, neurodegeneration, and neuronal cell
death. A variety of factors including oxidative stress [49], post-translational modifications [50–52],
proteolysis [53,54]; and fatty acids [55–57], phospholipids [55,58], and metal ion [59,60] concentrations
have been shown to affect α-synuclein aggregation. Mitochondrial dysfunction and energy failure
induced by environmental toxicants may also lead to α-synuclein misfolding and aggregation through
impairment in the protein quality control mechanisms. Importantly, there is a growing body of
evidence that indicates that α-synuclein is localized to the mitochondria under both normal and stress
conditions [61]. α-Synuclein may play a role in regulating mitochondrial function, in which either the
overexpression or lose of α-synuclein function may result in mitochondrial damage and cell death.
So, α-synuclein also plays a prominent role in idiopathic PD. Again, PD incidences may increase from
combined genetic and environmental factors.
Metabolites 2017, 7, 22  5 of 26 
 
(61–95), which is critical for protein aggregation and is commonly referred to as the non-amyloid-β 
component of AD amyloid plaques (NAC) (Figure 3b). α-Synuclein is an abundant neuronal protein 
(~1% of cytosol proteins) that is expressed throughout the brain with particularly high levels in the 
substantia nigra. α-Synuclein is primarily located in the presynaptic terminal of neurons. Thus, the 
protein may play a role in regulating the release of dopamine or the supply of synaptic vesicles. 
Genetic mutations in α-synuclein (SNCA) [9,10] or overexpression due to multiplication of SNCA 
[44] have been associated with familial and sporadic PD (Figure 3b). Oligomerization of α-synuclein 
and the resulting fibril formation is central to the pathogenesis of PD (Figure 2b). α-Synuclein 
aggregates have been shown to bind lipid membranes, to form pore-like structures, and to increase 
membrane per eability [45–48]. The resulting α-synuclein aggregates cause neuroinflammation, 
neurodegeneration, and neuronal cell death. A variety of factors including oxidative stress [49], 
post-translational modifications [50–52], proteolysis [53,54]; and fatty acids [55–57], phospholipids 
[55,58], and metal ion [59,60] concentrations have been shown to affect α-synuclein aggregation. 
Mitochondrial dysfunction and energy failure induced by environmental toxicants may also lead to 
α-synuclein misfolding and aggregation through impairment in the protein quality control 
mechanisms. Importantly, there is a growing body of evidence that indicates that α-synuclein is 
localized to the mitochondria under both normal and stress conditions [61]. α-Synuclein may play a 
role in regulating mitochondrial function, in which either the overexpression or lose of α-synuclein 
function may result in mitochondrial damage and cell death. So, α-synuclein also plays a prominent 
role in idiopathic PD. Again, PD incidences may increase from combined genetic and environmental 
factors.  
 
(a) (b) 
Figure 3. Structure of α-synuclein: (a) Schematic representation of micelle-bound α-synuclein (α-syn; 
Protein Data Bank ID: 1XQ8) [40]. The N-terminal region, the non-amyloid-β component of 
Alzheimer’s disease amyloid plaques (NAC) region and the C-terminal part are colored blue, orange 
and red, respectively. Numbers refer to amino acid residues flanking the different regions. 
Reproduced with permission from [39]. (b) α-Synuclein protein domain structure. α-Syn is a 
140-amino-acid protein and its sequence can be divided into three regions with distinct structural 
characteristics. The highly conserved N-terminal domain encodes for a series of imperfect 11 amino 
acid repeats with a consensus motif of KTKEGV reminiscent of the lipid-binding domain of 
apolipoproteins, which in certain conditions forms amphipathic helices. The six missense mutations 
known to cause familial PD (A30P, E46K, H50Q, G51D, A53E, and A53T) lie in the amphipathic 
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been used for a given metabolomics study, in which the choice of instrumentation has been 
primarily decided upon based on an investigator’s experience and expertise, instead of the needs of 
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Figure 3. Structure of α-synuclein: (a) Schematic representation of micelle-bound α-synuclein (α-syn;
Protein Data Bank ID: 1XQ8) [40]. The N-terminal region, the non-amyloid-β component of Alzheimer’s
disease amyloid plaques (NAC) region and the C-terminal part are colored blue, orange and red,
respectively. Numbers refer to amino acid residues flanking the different regions. Reproduced with
permission from [39]. (b) α-Synuclein protein domain structure. α-Syn is a 140-amino-acid protein
and its sequence can be divided into three regions with distinct structural characteristics. The highly
conserved N-terminal domain encodes for a series of imperfect 11 amino acid repeats with a consensus
motif of KTKEGV reminiscent of the lipid-binding domain of apolipoproteins, which in certain
conditions forms amphipathic helices. The six missense mutations known to cause familial PD
(A30P, E46K, H50Q, G51D, A53E, and A53T) lie in the amphipathic region, suggesting an important
function for this region of the protein. The central hydrophobic region (non-amyloid-β component
or NAC domain) of α-synuclein is associated with an increased propensity of the protein to form
fibrils [62]. The acidic C-terminal tail contains mostly negatively charged residues and is largely
unfolded. Reproduced with permission from [63].
2. NMR and MS Metabolomics Protocol to Investigate PD
2.1. Combining NMR and MS Improves Coverage of the Metabolome
Nuclear magnetic resonance (NMR) [64] and mass spectrometry (MS) [65] have been the primary
analytical tools used to obtain metabolomics datasets. Historically, only NMR or MS has been used for
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a given metabolomics study, in which the choice of instrumentation has been primarily decided upon
based on an investigator’s experience and expertise, instead of the needs of the study. Consequently,
a suboptimal analysis of the metabolome is likely to occur. In fact, NMR and MS are inherently
complementary and when employed together provide a broader and more accurate coverage of the
metabolome [66,67]. While the number of studies is still limited, a few projects that have used both
NMR and MS have observed a common trend [68–70]. A set of metabolites was only observable by
NMR, while a second set of metabolites was only detected by MS. A smaller subset of metabolites was
observed by both NMR and MS. Simply, NMR only observes the most abundant metabolites (≥1 µM)
and MS only observes the metabolites that readily ionize. There are other important differences
between NMR and MS. NMR requires minimal sample handling before data collection, is easily
quantifiable, and provides multiple means of metabolite identification. In addition to the higher
sensitivity, (femtomolar to attomolar), MS also has a higher resolution (~103–104) and dynamic range
(~103–104). However, chromatography is commonly required for MS because of the relatively narrow
nominal mass and mass defect distribution of the metabolome [71]. The use of chromatography has its
own limitations and may also lead to a loss of observable metabolites for a variety of reasons [72–76].
Simply, NMR and MS have unique sets of strengths and limitations and both analytical methods
beneficially contribute to a metabolomics study. In fact, a number of recent methods highlight the
benefits of combining NMR and MS to improve the accuracy of metabolite identification or for
identifying unknown metabolites [77–81].
2.2. Combined NMR and MS Metabolomics Methodology
Towards this end, we recently optimized sample preparation, data collection, and data handling
protocols to effectively integrate direct-infusion electrospray ionization mass spectrometry (DI-ESI-MS)
data with 1D 1H NMR spectra (Figure 4) [82,83]. By splitting metabolite extracts optimized for NMR
acquisition and by diluting the MS-bound aliquots tenfold in H2O/methanol/formic acid (49.57 :
49.75 : 0.5), we obtained samples suitable for NMR and DI-ESI-MS while avoiding chromatographic
separations. We also optimized several DI-ESI-MS ion source conditions to maximize the quality of
the MS metabolomics data: sampling cone voltage (SCV) of 40 V, extraction voltage (ECV) of 4.0 V,
desolvation temperature of 150 ◦C, desolvation gas flow of 500 L/h, and a cone gas flow of 0 L/h.
We preprocessed the acquired mass spectra with background subtraction, followed by uniform binning
with a 0.5 m/z bin size and spectral noise region removal. NMR spectra were processed with our
MVAPACK [84] software and automatically phased and normalized using our phase-scatter correction
(PSC) algorithm [85]. Chemical shift regions containing spectral baseline noise or solvent signals
were removed based on our previously developed protocols [86,87]. Binning was performed using
an adaptive intelligent binning algorithm [88] implemented in MVAPACK [84] that minimizes the
splitting of signals between multiple bins.
Integrating MS and NMR data clearly resulted in better class separation and tighter within-class
variation than using only NMR or MS datasets (Figure 5). This was accomplished by incorporating
multivariate statistical techniques to properly handle multiple analytical datasets [89–91]—multiblock
principal component analysis (MB-PCA) and multiblock partial least squares (MB-PLS)—into
MVAPACK [84]. Multiblock methods are similar to traditional PLS and PCA, but provide a means
for analyzing data from multiple analytical sources [89–91]. Simply put, the NMR and MS spectral
data are placed into separate “blocks,” which allows for the generation and simultaneous usage of
within-block and between-block data correlations. The inclusion of MB-PLS also led to the use of
backscaled loadings to identify biologically important metabolites that contributed significantly to
group separation. Importantly, these NMR and MS spectral changes are now identified as being
statistically correlated. In addition to MB-PCA and MB-PLS, the data were jointly modeled using
multiblock orthogonal projections to latent structures (MB-OPLS), which corroborated the MB-PLS
analysis while better differentiating group separations [92]. By effectively integrating NMR and MS
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datasets, we could thoroughly analyze the metabolic changes to human dopaminergic cells resulting
from treatments with toxins that were not achievable with just the NMR or MS data.Metabolites 2017, 7, 22  7 of 26 
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Figure 4. A flow chart illustrating our protocol f r c mbining NMR and S datasets for metabol mics.
2.0 L of a single metabolite extract was split into 1.8 mL a d 0.2 for NMR and MS analysis,
respectively. Spectral binning of the NMR data used adaptive intelligent binning. For MS, the background
is first subtracted before pectral binning. Spectral binning of the MS data used fixed binning with a set
bin width of 0.5 m/z. Noise removal and nor alization were separately applied to the NMR and MS
datasets. The NMR and MS datasets were then modeled by MB-PCA and MB-PLS. The resulting block
scores and loadings are then analyzed for significantly contributing metabolites. Reproduced with
permission from [82].
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A detailed analysis of the metabolic changes by NMR and MS verified that paraquat uniquely 
perturbed the metabolome of dopaminergic neurons. For example, the S-plot (Figure 6a) generated 
from the MB-PLS-DA model identified metabolites significantly perturbed in dopaminergic neurons 
following paraquat treatment. Specifically, an increase in citrate, glucose 6-phosphate/fructose 
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Figure 5. Scores generated from (a) PCA of 1D 1H NMR spectra; (b) PCA of DI-ESI-MS spectra;
and (c) MB-PCA of 1D 1H NMR and DI-ESI-MS spectra of metabolomes extracted from human
dopaminergic neuroblastoma cells treated with environmental/mitochondrial toxins. The ellipses
in the PCA score plots correspond to the 95% confidence limits from a normal distribution for each
cluster. Symbols designate the following classes: Control (•); Rotenone (•); 6-OHDA (•); MPP+ (•);
and Paraquat (•). Reproduced with permission from [82].
3. PD and Mitochondrial/Environmental Toxins
3.1. Paraquat Induces Unique Metabolic Changes
In a previous study, human dopaminergic neuroblastoma cells (SK-N-SH) were treated with sublethal
doses of environmental toxins known to induce dopaminergic cell death. Specifically, cells were treated
with MPP+, 50 µM 6-OHDA, 0.5 mM paraquat, or 4.0 µM rotenone for 24 h [82,83]. The metabolome
was extracted as described above (Figure 4) and analyzed with both 1D 1H NMR and DI-ESI-MS.
The resulting MB-PCA model (Figure 5c) was valid based on both a CV-ANOVA p value of 1.7× 10−12
and response permutation testing that yielded a p value equal to zero. The MB-PCA model yielded a
clear separation between the control group and the four toxin treatments. Furthermore, the control and
paraquat groups were separated from the other toxin treatments. Also, the MPP+ treatment group was
significantly separated from 6-OHDA and rotenone treatments. Again, these group separations were
not apparent if only the NMR or MS dataset was used (Figure 5). More importantly, 6-OHDA, MPP+,
paraquat, and rotenone have been routinely used as experimental models of PD since they all result
to a certain and variable extent in dopaminergic neuron cell death and PD-like symptoms in animal
models [93]. Nevertheless, our analysis clearly indicates that the metabolic impact of these four toxins
is unique and, consequently, the molecular mechanism that results in neuronal cell death must be
different. Since paraquat treatment resulted in the largest metabolome changes relative to untreated
controls, we focused our further investigation on the molecular mechanism of PD on paraquat.
A detailed analysis of the metabolic changes by NMR and MS verified that paraquat uniquely
perturbed the metabolome of dopaminergic neurons. For example, the S-plot (Figure 6a) generated
from the MB-PLS-DA model identified metabolites significantly perturbed in dopaminergic neurons
following paraquat treatment. Specifically, an increase in citrate, glucose 6-phosphate/fructose
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6-phoshate, heptose (sedoheptulose), and hexose (glucose or myoinositol), and a decrease in lactate,
glutamate, dopamine, and phospho-aspartate were clearly observed. A similar comparison was made
between paraquat and the other toxins to determine if these metabolomic changes were unique to
paraquat. The resulting Shared and Unique Structures (SUS) plot (data not shown), which is a union
of two S-plots (paraquat vs. controls, and paraquat vs. MPP+, rotenone and 6-OHDA), verified
that the changes in citrate, glucose 6-phosphate/fructose 6-phoshate, hexose, lactate, and dopamine
were all a unique neuronal response to paraquat. Metabolome changes were further characterized by
monitoring changes in the distribution and incorporation of 13C-carbons into metabolites (Figure 7).
This was accomplished by interrogating intensity changes in 2D 1H-13C HSQC experiments after
the addition of 13C glucose to the cell culture medium. Paraquat treatment resulted in an increase in
glucose, glucose 6-phosphate, fructose-6-phosphate, glucose-1-phosphate, and glucono-1,5-lactone,
which are associated with the pentose phosphate pathway (PPP). Importantly, these metabolic changes
are consistent with the observed changes in the 1D 1H NMR and DI-ESI-MS spectral data. Paraquat
also decreased purine levels (ATP, ADP, and AMP) and metabolites associated the glycolytic pathway
[3-phospho glycerate, dihydroxyacetone phosphate (DHAP or glycerone phosphate), lactate, and
alanine]. A decrease in extracellular glucose, lactate, and alanine was also observed. Furthermore,
a large increase in citrate and a decrease in aspartate were observed following paraquat treatment.
This is consistent with the inhibition of aconitase by paraquat-induced superoxide anion formation [94],
since aconitase converts citrate to isocitrate in the tricarboxylic acid cycle (TCA). Also, aspartate is
generated from oxaloacetate, which is produced from the TCA cycle. Finally, paraquat treatment
also resulted in a decrease in total reduced (GSH) and oxidized (GSSG) glutathione. Critically, GSH
depletion is an important contributor to oxidative stress and dopaminergic cell death [95]. Also, a
decrease in GSH is one of the earliest biochemical alterations detected in incidental Lewy body disease,
which is considered an asymptomatic precursor to PD [96]. A flow cytometry experiment confirmed a
76.4% decrease in GSH 48 h after treatment with paraquat. Also, cell death was correlated with the
GSH decrease. In total, the observed metabolite changes by NMR and MS demonstrate that paraquat
increased PPP metabolite accumulation while decreasing glycolysis and impairing the TCA cycle.
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Figure 6. (a) Alterations in citrate, glucose 6-phosphate/fructose 6-phosphate, lactate, and glucose 
content are specific for paraquat treatment. S-plot was generated from the combined MB-PLS-DA of 1D 
1H NMR spectra and DI-ESI-MS spectra. The S-plot was used to identify metabolites that significantly 
contribute to the class separation between untreated controls and paraquat treatment. The metabolites 
located in the upper right quadrant increased significantly while those located in the lower left 
quadrant significantly decreased after paraquat exposure. Reproduced with permission from [83]. (b) 
Western blot analysis of changes in glucose-6-phosphate dehydrogenase (G6PD) expression induced 
by paraquat. Paraquat induces an increase in the expression levels of G6PD. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) levels are used as loading controls for WBs. The changes 
observed in GAPDH levels might reflect of overall cell death (overall decrease in protein content) 
induced by PQ. Reproduced with permission from [83]. 
Figure 6. (a) Alterations in citrate, glucose 6-phosphate/fructose 6-phosphate, lactate, and glucose
content are specific for paraquat treatment. S-plot was generated from the combined MB-PLS-DA of 1D
1H NMR spectra and DI-ESI-MS spectra. The S-plot was used to identify metabolites that significantly
contribute to the class separation between untreated controls and paraquat treatment. The metabolites
located in the upper right quadrant increased significantly while those located in the lower left quadrant
significantly decreased after paraquat exposure. Reproduced with permission from [83]. (b) Western
blot analysis of changes in glucose-6-phosphate dehydrogenase (G6PD) expression induced by
paraquat. Paraquat induces an increase in the expression levels of G6PD. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) levels are used as loading controls for WBs. The changes observed in
GAPDH levels might reflect of overall cell death (overall decrease in protein content) induced by PQ.
Reproduced with permission from [83].
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(50 μM) for 24 h in a glucose-free medium supplemented with 13C-glucose (3.5 g/L). Analysis of 2D 
1H-13C HSQC NMR spectra was used to evaluate changes in glucose-derived metabolites. Bar graphs 
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PPP and nucleotide biosynthesis and (b) glycolysis, the TCA cycle, and metabolites found 
accumulated in the extracellular media. Data represent means ± SD of 3 independent experiments. * p 
< 0.05, control vs. neurotoxin treatments. ATP/ADP/AMP, ATP or ADP or AMP; DHAP, 
Dihydroxyacetone phosphate; NADP/NADPH, NADP or NADPH; UDP/UMP, UDP or UMP. 
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major biological responses to paraquat toxicity. The proteomics analysis identified increases in 
glucose 6-phosphate dehydrogenase (G6PD), mitochondrial malate dehydrogenase, 
phosphoglycerate kinase 1 (PGK1), ATP-citrate synthase (CS), and pyruvate kinases isozymes 
M1/M2 and a decrease in lactate dehydrogenase A/B chains, which all correlate with the alterations 
in the PPP, TCA cycle, and glycolysis pathway identified from the metabolomics data. G6PD was of 
particular interest since it is a rate-limiting enzyme of the PPP and a major source of NADPH [97]. 
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data indicated that alterations in PPP and G6PD activity may be a result of paraquat toxicity. 
  
Figure 7. Paraquat induces selective changes in glucose metabolism, TCA cycle, and the PPP pathway.
Cells were treated with paraquat (0.5 mM), rotenone (4 µM), MPP+ (2.5 mM), or 6-OHDA (50 µM)
for 24 h in a glucose-free medium supplemented with 13C-glucose (3.5 g/L). Analysis of 2D 1H-13C
HSQC NMR spectra was used to evaluate changes in glucose-derived metabolites. Bar graphs indicate
the relative change in pe k inten ity (concentration) for metabolites associat with the (a) PPP and
nucleotid biosynthesis and (b) glycolysis, the TCA ycle, and metaboli es found ccumulated n the
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neurotoxin treatments. ATP/ADP/AMP, ATP or ADP or AMP; DHAP, Dihydroxyacetone phosphate;
NADP/NADPH, NADP or NADPH; UDP/UMP, UDP or UMP. Reproduced with permission from [83].
3.2. Glucose 6-Phosphate Dehydrogenase Regulates Paraquat Toxicity
Metabolomics is a valuable tool of systems biology and provides a unique and complementary
view relative to traditional cellular assays and molecular biology data. In this context, the value and
validity of metabolomics data are greatly enhanced when combined with other experimental results.
Thus, our metabolomics data were supplemented with a proteomics analysis following 24-h treatment
of human dopaminergic neuroblastoma cells with paraquat. As commonly observed with proteomics
data, a number of proteins across a variety of biological processes exhibited significant upregulation or
downregulation due to exposure to paraquat. Consequently, it is difficult to ascertain which changes
in protein expression levels are primary responses to paraquat toxicity and which are downstream or
secondary effects. However, by combining the metabolomics and proteomics data it was possible to
identify overlapping metabolic processes that likely represent major biological responses to paraquat
toxicity. T e proteomics analysis identified increases in glucose 6-phosphate dehydrogenase (G6PD),
mitochondrial malate dehydrogenase, phosphoglycerate kinase 1 (PGK1), ATP-citrate synthase (CS),
and pyruvate kinases isozymes M1/M2 and a dec ease lactate dehydrogena A/B chains, which
ll correlate with the alterati ns in the PPP, TCA cycle, and glycoly is p thway identifi from th
metabolomics data. G6PD was of particular interest since it is a rate-limiting enzyme of the PPP and a
major source of NADPH [97]. The proteomics data were confirmed by Western blot (Figure 6b) and
indicate that G6PD expression increased proportional to an increase in paraquat dosage. Thus, the
metabolomics and proteomics data indicated that alterations in PPP and G6PD activity may be a result
of paraquat toxicity.
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3.3. Paraquat Hijacks the Pentose Phosphate Pathway
Human dopaminergic neuroblastoma cells were transduced with adenovirus encoding for human
G6PD (AdG6PD) or empty adenovirus (AdEmpty) to further investigate the role of G6PD in paraquat
toxicity. G6PD overexpression increased cell death and oxidative death as a result of paraquat treatment,
but, importantly, no change was observed when cells were exposed to other toxins (Figure 8a).
Conversely, paraquat-induced toxicity, mitochondrial ROS formation, and GSH depletion were reversed
when G6PD was inhibited with 6-aminonicotinamide (6-AN) (Figure 8b). Again, 6-AN had no effect on
cell death or GSH depletion when neuronal cells were treated with rotenone, MPP+, or 6-OHDA instead
of paraquat. These observations are consistent with the recycling of NADPH from NADP+ by G6PD
being uniquely required for the redox cycling of paraquat to produce ROS. In effect, paraquat would
be expected to outcompete NADPH-dependent antioxidant systems. As such, unpublished results
from our group have demonstrated that depletion of GSH is not prevented by overexpression of GSH
reductase. NADPH can also be produced by 6-phosphogluconate dehydrogenase (PGD), malic enzyme
(malate dehydrogenase, MDH), and isocitrate dehydrogenase (IDH) [97]. Interestingly, paraquat
treatment also increased the expression levels of malate dehydrogenase, which may also contribute to
paraquat’s redox cycle in the mitochondria. The observed changes in the metabolome and proteome
for human dopaminergic neuroblastoma cells following exposure to paraquat are summarized in
Figure 9. Our results suggest that paraquat hijacks the PPP to increase NADPH-reducing equivalents
and stimulate paraquat redox cycling, oxidative stress, and cell death.
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Figure 8. Paraquat-induced cell death is selectively regulated by glucose 6-phosphate dehydrogenase 
and the pentose phosphate pathway. (a) Cell death induced by paraquat (0.5 mM), rotenone (4 μM), 
MPP+ (2.5 mM) or 6-OHDA (50 μM) after 48 h of treatment, was simultaneously evaluated by flow 
cytometry using PI and mBCl. Cell death is observed as an increase in PI uptake. Data is represented 
as fold increase in the mean PI fluorescence and are means ± SE of three independent experiments. * p 
< 0.05, Empty vs. G6PD values. Reproduced with permission from [83]. (b) Cell death induced by 
paraquat was evaluated in the presence or absence of 6-aminonicotinamide (6-AN, 1 mM). Cell death 
is represented as an increase in the population of cells (%) with increased PI fluorescence. 
Reproduced with permission from [98]. 
Figure 8. Paraquat-induced cell death is selectively regulated by glucose 6-phosphate dehydrogenase
and the pento osphate pathway. (a) Cell death induced by paraquat (0.5 mM), rotenone (4 µM),
M P+ (2.5 m ) r 6-OHDA (50 µM) after 48 h of treatment, was simultaneously eval ated by flow
cytometry using PI and mBCl. Cell death is observed as an increase in PI uptake. Data is represented
as fold increase in the mean PI fluorescence and are means ± SE of three independent experiments.
* p < 0.05, Empty vs. G6PD values. Reproduced with permission from [83]. (b) Cell death induced by
paraquat was evaluated in the presence or absence of 6-aminonicotinamide (6-AN, 1 mM). Cell death
is represented as an increase in the population of cells (%) with increased PI fluorescence. Reproduced
with permission from [98].
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PGK1, phosphoglycerate kinase (EC:2.7.2.3); PGM, phosphoglucomutase (EC:5.4.2.2); PFK, 
6-phosphofructokinase 1 (EC:2.7.1.11); RPI, ribose 5-phosphate isomerase A (EC:5.3.1.6); SDH, 
succinate dehydrogenase (EC:1.3.5.1); TPI, triosephosphate isomerase (EC:5.3.1.1); TAL, 
transaldolase (EC:2.2.1.2); TKT, transketolase (EC:2.2.1.1). Reproduced with permission from [83]. 
Figure 9. Paraquat hijacks the pentose phosphate pathway to induce oxidative stress and cell death.
Our results demonstrate that paraquat induces an increase in the PPP (highlighted in green), which is
reflected by an i crease in glucose uptake, and in glucose 6-phosphate, glucono 1,5-lactone, erythrose
4-phosphate, and fructose 6-phosphate content (red arr ws). In addition, paraquat decreases glycolysis
as demonstrated by a decrease in 3-phosphoglycerate, alanine and lactate levels (green arrows). These
metabolic changes w r also paralleled by: (1) an increase in G6PD (the rate-limiting enzyme in the PPP),
and the expression levels of citrate synthase, pyruvate kina es M1/M2; a d (2) a decre se in lactate
dehydroge ase A/B chains, whi h participate in glycolysis nd the TCA cycle (highli hted in orange).
Paraquat also induced an increase in citr te accumulation which is as oc ated to the well-kn wn
inhibitory effect on aconitase (highlighted in orange). An abnormal increase n citrate levels has been
reported to exe t n inhibitory effect on glycolysis by allosteric inhibition of PFK (broke red line), which
explains why an increase glucose uptake a d impaired TCA cycle is not translated t an upregulation
in glycolysis. Modulation of G6PD levels and activity was directly linked to paraquat toxicity and
oxidative stress. 6-AN, 6-aminonicotinamide, ACO, aconitase or aconitate hydratase (EC:4.2.1.3; ADC,
aspartate 4-decarboxylase (EC:4.1.1.12); ALDO, fructose-bisphosphate aldolase (EC:4.1.2.13); ALT,
alanine transaminase (EC:2.6.1.2); CS, citrate synthase (EC:2.3.3.1); FBP, fructose-1,6-bisphosphatase
I (EC:3.1.3.11); FUM, fumarate hydratase (EC:4.2.1.2); G6PD, glucose-6-phosphate 1-dehydrogenase
(EC:1.1.1.49); GAPDH, glyceraldehyde 3-phosphate dehydrogenase (EC:1.2.1.12); GLDH, glutamate
dehydrogenase, (EC: 1.4.1.2); GLS, glutaminase (EC: 3.5.1.2); GOT1, aspartate aminotransferase,
cytoplasmic (EC:2.6.1.1); GPI, glucose-6-phosphate isomerase (EC:5.3.1.9); HK, hexokinase (EC:2.7.1.1);
IDH, isocitrate dehydrogenase (EC:1.1.1.42); LDH, L-lactate dehydrogenase (EC:1.1.1.27); MDH, malate
dehydrogenase (EC:1.1.1.37); OGDH, 2-oxoglutarate dehydrogenase, (EC:1.2.4.2); LSC, succinyl-CoA
synthetase (EC:6.2.1.4 6.2.1.5); PC, pyruvate carboxylase (EC:6.4.1.1); PGD, 6-phosphogluconate
dehydrogenase (EC:1.1.1.44); PDH, pyruvate dehydrogenase (EC:1.2.4.1); PGK1, phosphoglycerate
kinase (EC:2.7.2.3); PGM, phosphoglucomutase (EC:5.4.2.2); PFK, 6-phosphofructokinase 1 (EC:2.7.1.11);
RPI, ribose 5-phosphate isomerase A (EC:5.3.1.6); SDH, succinate dehydrogenase (EC:1.3.5.1); TPI,
triosephosphate isomerase (EC:5.3.1.1); TAL, transaldolase (EC:2.2.1.2); TKT, transketolase (EC:2.2.1.1).
Reproduced with permission from [83].
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3.4. Glucose Metabolism Regulates Paraquat Toxicity
We further investigated the role of glucose metabolism on paraquat toxicity based on the prior
observations that metabolites derived from 13C-glucose are uniquely perturbed by paraquat exposure
and the hijacking of the PPP. Consequently, glucose availability significantly impacted the survivability
of rat dopaminergic mesencephalic cell line N27 following exposure to paraquat. Specifically, glucose
deprivation increased cell survival (Figure 10a). Also, replacing glucose with galactose protected cells
from paraquat toxicity. Galactose directs metabolism from glycolysis into glutaminolysis and OXPHOS
phosphorylation for ATP production. An inhibition in glycolysis for cells grown in glucose-free or
galactose-supplemented media was verified by changes in the extracellular medium acidification (ECAR)
(Figure 10b). Furthermore, treatment of cells with 2-deoxy-D-glucose (2-DG), which is a hexokinase
inhibitor that prevents the production of glucose-6-phosphate, also provided protection from paraquat
toxicity (Figure 10c). These results, in total, demonstrate that glucose metabolism contributes to the
death of cells following treatment with paraquat at ≥100 µM.
Metabolites 2017, 7, 22  13 of 26 
 
3.4. Glucose Metabolism Regulates Paraquat Toxicity 
We further investigated the role of glucose metabolism on paraquat toxicity based on the prior 
observations that metabolites derived from 13C-glucose are uniquely perturbed by paraquat 
exposure and the hijacking of the PPP. Consequently, glucose availability significantly impacted the 
survivability of rat dopaminergic mesencephalic cell line N27 following exposure to paraquat. 
Specifically, glucose deprivation increased cell survival (Figure 10a). Also, replacing glucose with 
galactose protected cells from paraquat toxicity. Galactose directs metabolism from glycolysis into 
glutaminolysis and OXPHOS phosphorylation for ATP production. An inhibition in glycolysis for 
cells grown in glucose-free or galactose-supplemented media was verified by changes in the 
extracellular medium acidification (ECAR) (Figure 10b). Furthermore, treatment of cells with 
2-deoxy-D-glucose (2-DG), which is a hexokinase inhibitor that prevents the production of 
glucose-6-phosphate, also provided protection from paraquat toxicity (Figure 10c). These results, in 
total, demonstrate that glucose metabolism contributes to the death of cells following treatment with 
paraquat at ≥100 μM. 
The metabolomics analysis indicated both an increase in intracellular glucose and a 
corresponding decrease in extracellular glucose after exposure to paraquat. These observations 
suggested that paraquat treatment increases glucose uptake. A fluorescently labeled analog of 
glucose (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose, 2-NBDG) was used to 
monitor changes in glucose uptake due to paraquat exposure. Correspondingly, neuronal cells 
treated with paraquat exhibited a >60% increase in glucose uptake in response to paraquat treatment 
(Figure 11a), which is consistent with the metabolomics data. Glucose uptake is regulated by a 
saturable transport system involving the Na+-independent glucose transporters (GLUT), and the 
Na+-dependent glucose transporters (SGLT). Exposure to paraquat resulted in a significant increase 
in the translocation of SGLT1 and GLUT4 transporters to the plasma membrane. Consequently, 
inhibiting glucose uptake with STF-31, a GLUT inhibitor, (Figure 11b) or ascorbic acid, a competitive 
inhibitor of glucose, decr ased paraqu t toxicity. Again, these results clearly demon trate that 
glucose metabolism is an important contributor to paraquat-induced cell death. 
 
(a) 
 
(b) 
 
(c) 
Figure 10. Inhibition of glucose metabolism protects against paraquat toxicity. Rat dopaminergic N27 
cells were grown in culture media with or without glucose, or in a glucose-free medium 
supplemented with galactose. When indicated, cells were treated with PQ or MPP+ (2.5 mM) for 48 h 
in the presence or absence of 2-DG. (a,c) Cell survival was determined by the simultaneous analysis 
of plasma membrane integrity (PI uptake) and intracellular GSH content (mBCl fluorescence). Bar 
graphs represent % s of viable cells (cell survival) and data are means ± SE of at least n = 3 
independent experiments. (b) Glycolysis rates and glycolytic reserve capacity of cells were 
evaluated by changes in the ECAR sensitive to 2-DG. Glycolysis is observed as an increase in ECAR 
when switching cells from a glucose-free environment (NG) to a medium containing 10 mM 
glucose. Glycolytic reserve capacity is determined by addition of oligomycin. Data are means ± SE 
of at least n = 3 independent experiments and are represented with respect to control (+ glucose). 
Two-way ANOVA Holm–Sidak post hoc test: a, p < 0.05 vs. no PQ or MPP+ within the 
corresponding category of ± glucose, galactose or 2-DG; b, p < 0.05, vs. + glucose, within the 
corresponding toxicant treatment. t-test: * p 0.05, vs. + glucose. Reproduced with permission from 
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Figure 10. Inhibition of glucose metabolism protects against paraquat toxicity. Rat dopaminergic N27
cells were grown in culture media with or without glucose, or in a glucose-free medium supplemented
with galactose. When indicated, cells were treated with PQ or MPP+ (2.5 mM) for 48 h in the
presenc or absence of 2-DG. (a,c) Cell survival was determin d by the simultaneous analysis of
plasma membrane integrity (PI uptake) and intracellul r GSH content (mBCl fluorescence). Bar graphs
re resent % s of viable cells (cell survival) and data are means ± SE of at least n = 3 indep nde t
experiments. (b) Glycolysis rates and glycolytic reserve capacity of cells were evaluated by changes
in the ECAR sensitive to 2-DG. Glycolysis is observed as an increase in ECAR when switching cells
from a glucose-free environment (NG) to a medium containing 10 mM glucose. Glycolytic reserve
capacity is determined by addition of oligomycin. Data are means ± SE of at least n = 3 independent
experiments and are represented with respect to control (+glucose). Two-way ANOVA Holm–Sidak
post hoc test: a, p < 0.05 vs. no PQ or MPP+ within the corresponding category of ±glucose, galactose
or 2-DG; b, p < 0.05, vs. +glucose, within the corresponding toxicant treatment. t-test: * p < 0.05, vs.
+glucose. Reproduced with permission from [98].
The metabolomics analysis indicated both an increase in intracellular glucose and a corresponding
decrease in extracellular glucose after exposure to paraquat. These observations suggested that
paraquat treatment increases glucose uptake. A fluorescently labeled analog of glucose (2-[N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose, 2-NBDG) was used to monitor changes
in glucose uptake due to paraquat exposure. Correspondingly, neuronal cells treated with paraquat
exhibited a >60% increase in glucose uptake in response to paraquat treatment (Figure 11a), which
is consistent with the metabolomics data. Glucose uptake is regulated by a saturable transport
system involving the Na+-independent glucose transporters (GLUT), and the Na+-dependent glucose
transporters (SGLT). Exposure to paraquat resulted in a significant increase in the translocation of
SGLT1 and GLUT4 transporters to the plasma membrane. Consequently, inhibiting glucose uptake
with STF-31, a GLUT inhibitor, (Figure 11b) or ascorbic acid, a competitive inhibitor of glucose,
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decreased paraquat toxicity. Again, these results clearly demonstrate that glucose metabolism is an
important contributor to paraquat-induced cell death.Metabolites 2017, 7, 22  14 of 26 
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Figure 11. Paraquat increases glucose transport and the translocation of glucose transporters.
Cells were treated with PQ for 48 h. (a) Glucose transport evaluated by the uptake 2-NBDG;
(b) the survival of cells treated with PQ in the presence or absence of STF-31 as etermined as
explained in Figure 10. The bar graph represents %s of viable cells (cell survival). Data in all graphs are
means ± SE of at least n = 3 independent experiments. Two-way ANOVA Holm–Sidak post hoc test:
c, p < 0.05 vs. no PQ within the corresponding ±STF-31 or phlorizin category; d, p < 0.05 vs. control (no
glucose transport inhibitor) within the corresponding PQ concentration. Reproduced with permission
from [98].
3.5. Paraquat Induced Metabolic Dysfunction in the Mice Midbrain and Striatum
To further substantiate the validity of our in vitro findings that paraquat uniquely perturbs the
metabolome of dopaminergic neurons, we evaluated the metabolic dysfunction induced by chronically
treating C57BI/6 mice with paraquat. We observed that paraquat only induced statistically significant
changes to the metabolomes of the midbrain, which is the location of the substantia nigra and the
loss of dopaminergic neurons associated with PD; and to the striatum, which receive dopaminergic
signals from midbrain and controls motor function. Importantly, we observed changes to metabolites
associated with glycolysis (e.g., lactate), the TCA cycle (e.g., glutamate), and GSH metabolism
(e.g., glutathione), consistent with our in vivo results (Figure 12a). Paraquat was again observed
to induce a large accumulation of citrate consistent with the proposed inactivation of aconitase.
AMP-activated protein kinase (AMPK) is a metabolic master regulator that includes regulating glucose
uptake and, like other kinases, is regulated by phosphorylation (pAMPK) [99]. Consequently, chronic
paraquat treatment also resulted in a significant increase in pAMPK and its substrate acetyl-CoA
carboxylase (pACC) only in the midbrain and striatum of C57BI/6 mice (Figure 12b). These results
further corroborate the observation that paraquat modulates glucose metabolism and that the midbrain
and striatum are selectively sensitive to paraqu t toxicity.
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Figure 12. C57Bl/6J mice were exposed chronically to paraquat (PQ). One week after the final 
injection of PQ or PBS, animals were euthanized to isolate metabolites from the midbrain, striatum 
and cortex regions. Integrated positive and negative-ion DI-ESI-MS and 1D 1H NMR were used to 
characterize the alterations in the metabolic profiles of midbrain, striatum, and cortex regions from 
control and PQ-treated mice. (a) The percent fold-change for metabolites contributing to class 
separation as identified from OPLS-DA back-scaled loadings plots are plotted. The percent fold 
changes are all significant (p < 0.05) based on a paired t-test. The green bars indicate metabolites with 
a fold-increase after PQ treatment, whereas red bars indicate that a metabolite decreased after PQ 
treatment. Reproduced with permission from [98]. (b) Changes in the levels of phosphorylated (p) 
AMPKα1 induced by PQ were evaluated by western-bot (WB). Bar graphs represent the 
densitometry analysis of the corresponding WBs from three independent replicas. Data are 
represented as fold change vs. the indicated control. Reproduced with permission from [98].  
4. Synergy of α-Synuclein Genetic Mutations and Paraquat Toxicity 
4.1. α-Synuclein Potentiates Paraquat Toxicity and Metabolic Dysfunction 
PD is a probable multifactorial disease, in which exposure to an environmental toxin is likely 
one component in the development and progression of the disease. Overexpression and aggregation 
of α-synuclein and the subsequent formation of Lewy bodies are hallmarks of PD. Consequently, is 
there a synergistic relationship between α-synuclein and exposure to paraquat? The overexpression 
of wild-type (WT) α-synuclein or an A53T mutant (familial PD mutant [9,10]) did not result in any 
significant change in viability (Figure 13a). Conversely, treatment with paraquat resulted in a 
significant increase in cell death and a major perturbation in the metabolome (Figure 13). 
Specifically, the combination of paraquat and α-synuclein overexpression produced a more 
dramatic change in the metabolome than either paraquat treatment or α-synuclein overexpression 
alone. Importantly, the same results were obtained if either WT or A53T α-synuclein was 
overexpressed. A detailed analysis of the metabolic changes was then made using 2D 1H-13C HSQC 
experiments and following the 13C-carbon distribution resulting from 13C-glucose supplemented 
media (Figure 14a). Overexpression of α-synuclein and paraquat exposure resulted in an enhanced 
glucose accumulation, an impairment in glycolysis, and a reduction in glycolytic capacity and 
mitochondrial respiration (OCR/ECAR ratio) (Figure 14b).  
Figure 12. C57Bl/6J mice were exposed chronically to paraquat (PQ). One week after the final
injection of PQ or PBS, animals were euthanized to isolate metabolites from the midbrain, striatum
and cortex regions. Integrated positive and negative-ion DI-ESI-MS and 1D 1H NMR were used
to characterize the alterations in the metabolic profiles of midbrain, striatum, and cortex regions
from control and PQ-treated mice. (a) The percent fold-change for metabolites contributing to class
separation as identified from OPLS-DA back-scaled loadings plots are plotted. The percent fold
changes are all significant (p < 0.05) based on a paired t-test. The green bars indicate metaboli es wi h
a fold-increase after PQ treatment, whereas red bars indicate that a metabolite decreased after PQ
treatment. Reproduced with permission from [98]. (b) Changes in the levels of phosphorylated (p)
AMPKα1 induced by PQ were evaluated by western-bot (WB). Bar graphs represent the densitometry
analysis of the corresponding WBs from three independent replicas. Data are represented as fold
change vs. the indicated control. Reproduced with permission from [98].
4. Synergy of α-Synuclein Genetic Mutations and Paraquat Toxicity
4.1. α-Synuclein Potentiates Paraquat Toxicity and Metabolic Dysfunction
PD is a probable multifactorial disease, in which exposure to an environmental toxin is likely
one component in the development and progression of the disease. Overexpression and aggregation
of α-synuclein and the subsequent formation of Lewy bodies are hallmarks of PD. Consequently, is
there a synergistic relationship between α-synuclein and exposure to paraquat? The overexpression
of wild-type (WT) α-synuclein or an A53T mutant (familial PD mutant [9,10]) did not result in
any significant change in viability (Figure 13a). Conversely, treatment with paraquat resulted in a
significant increase in cell death and a major perturbation in the metabolome (Figure 13). Specifically,
the combination of paraquat and α-synuclein overexpression produced a more dramatic change in
the metabolome than either paraquat treatment or α-sy uclein overexpressi n alone. Importantly, the
same results were obtained if either WT or A53T α-synuclein was overexpressed. A detailed analysis
of the metabolic changes was then made using 2D 1H-13C HSQC experiments and following the
13C-carbon distribution resulting from 13C-glucose supplemented media (Figure 14a). Overexpression
of α-synuclein and paraquat exposure resulted in an enhanced glucose accumulation, an impairment
in glycolysis, and a reduction in glycolytic capacity and mitochondrial respiration (OCR/ECAR ratio)
(F gure 14b).
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Figure 13. α-Synuclein potentiates the metabolic dysfunction and toxicity induced by paraquat (PQ). 
N27 dopaminergic cells were transduced for 24 h with empty adenoviruses or adenoviruses 
encoding either WT or mutant A53T α-synuclein (6 MOI). (a) Cell survival after exposure to PQ for 
48 h was determined as explained in Figure 10. Bar graph represents percentage of viable cells (cell 
survival) and data are means ± SE of at least n = 3 independent experiments. (b) Cells were treated 
with 25 μM PQ for 24 h. Metabolites were extracted for NMR/MS metabolomics. 3D MB-PCA scores 
plot shows the changes in the metabolome based on distances between groups. The ellipsoids 
correspond to the 95% confidence limits from a normal distribution for each cluster. Six independent 
samples of metabolic extract were used for the MB-PCA multivariate analysis. Reproduced with 
permission from [98]. 
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Figure 14. α-Synuclein potentiates paraquat induced metabolic changes. (a) Paraquat N27 
dopaminergic cells were transduced for 24 h with empty adenoviruses or adenoviruses encoding 
either WT or mutant A53T α-synuclein (6 MOI). Cells were treated with 25 μM PQ for 24 h. 
Metabolites were extracted for NMR metabolomics. 2D 1H−13C HSQC NMR spectra from 13C glucose 
labeling experiments were used to evaluate the intracellular metabolic changes shown by the 
MB-PCA multivariate analysis. Data represent the mean of 3 independent replicates. * p < 0.05 vs. 
empty. (b) Cells were treated with 25 μM PQ for 12 h. Basal OCR and ECAR rates were determined 
after 1 h of incubation of cells with fresh medium. Data represent means ± SE of at least n = 3 
independent experiments. Reproduced with permission from [98].  
4.2. Glucose Metabolism Contributes to Synergistic Toxicity between Paraquat and α-Synuclein 
As described in Section 3.4, glucose metabolism was shown to regulate paraquat toxicity. 
Specifically, glucose deprivation protected dopaminergic cells from paraquat-induced cell death. 
Additionally, replacing glucose with galactose or the inhibition of glycolysis with 2-DG were also 
observed to prevent cell death from paraquat exposure (Figure 10). Furthermore, paraquat treatment 
was shown to cause an increase in glucose uptake, and inhibiting glucose uptake was also shown to 
Figure 13. α-Synuclein potentiates the metabolic dysfunction and toxicity induced by paraquat (PQ).
N27 dopaminergic cells were tr nsduc d for 24 h with empty adenoviruses or adenoviruses encoding
either WT or mutant A53T α-synuclein (6 MOI). (a) Cell survival after exposure to PQ for 48 h was
determined as explained in Figure 10. Bar graph represents percentage of viable cells (cell survival) and
data are means ± SE of at least n = 3 independent experiments. (b) Cells were treated with 25 µM PQ
for 24 h. Metabolites were extracted for NMR/MS metabolomics. 3D MB-PCA scores plot shows the
changes in the metabolome based on distances between groups. The ellipsoids correspond to the 95%
confidence limits from a normal distribution for each cluster. Six independent samples of metabolic
extract were used for the MB-PCA multivariate analysis. Reproduced with permission from [98].
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Figure 14. α-Synuclein potentiates paraquat induced metabolic changes. (a) Paraquat N27 
dopaminergic cells were transduced for 24 h with empty adenoviruses or adenoviruses encoding 
either WT or mutant A53T α-synuclein (6 MOI). Cells were treated with 25 μM PQ for 24 h. 
Metabolites were extracted for NMR metabolomics. 2D 1H−13C HSQC NMR spectra from 13C glucose 
labeling experiments were used to evaluate the intracellular metabolic changes shown by the 
MB-PCA multivariate analysis. Data represent the mean of 3 independent replicates. * p < 0.05 vs. 
e pty. (b) Cell  re tre ted with 25 μM PQ for 12 h. Basal OCR and ECAR ates were det rmi ed 
after 1 h of incubation of cells with fresh medium. Data represent means ± SE of at least n = 3 
independent experiments. Reproduced with permission from [98].  
4.2. Glucose Metabolism Contributes to Synergistic Toxicity between Paraquat and α-Synuclein 
As described in S ction 3.4, glucose metabolism was show  to regul  paraquat tox city. 
Sp cifically, glucose deprivation protected dopaminergic c lls from paraquat-induced cell death. 
Additionally, replacing glucose with galactose or the inhibition of glycolysis with 2-DG were also 
observed to prevent cell death from paraquat exposure (Figure 10). Furthermore, paraquat treatment 
was shown to cause an increase in glucose uptake, and inhibiting glucose uptake was also shown to 
Figure 14. α-Synuclein potentiates paraquat induced metabolic changes. (a) Paraquat N27 dopaminergic
cells were transduced for 24 h with empty adenoviruses or adenoviruses encoding either WT or mutant
A53T α-synuclein (6 MOI). Cells were treated with 25 µM PQ for 24 h. Metabolites were extracted for
NMR metabolomics. 2D 1H−13C HSQC NMR spectra from 13C glucose labeling experiments were
used to evaluate the intracellular metabolic changes shown by the MB-PCA multivariate analysis. Data
represent the mean of 3 independent replicates. * p < 0.05 vs. empty. (b) Cells were treated with 25 µM
PQ for 12 h. Basal OCR and ECAR rates were determined after 1 h of incubation of cells with fresh
medium. Data represent means ± SE of at least n = 3 independent experiments. Reproduced with
permission fro [98].
4.2. Glucose Metabolism Contributes to Syn rgistic Toxicity betw en Paraquat and α-Synucl in
As described in Section 3.4, glucose metabolism was shown to regulate paraquat toxicity.
Specifically, glucose deprivation protected dopaminergic cells from paraquat-induced cell death.
Additionally, replacing glucose with galactose or the inhibition of glycolysis with 2-DG were also
observed to prevent cell death from paraquat exposure (Figure 10). Furthermore, paraquat treatment
was shown to cause an increase in glucose uptake, and inhibiting glucose uptake was also shown
Metabolites 2017, 7, 22 17 of 26
to provide protection against paraquat toxicity (Figure 11). Finally, the inhibition of PPP by 6-AN
(Figure 8b) significantly increased cell survival following exposure to paraquat. These results raise the
question: does glucose metabolism play a similar role and contribute to the observed synergistic toxicity
between paraquat and α-synuclein? To address this question, we repeated all of the above experiments
with the addition of the overexpression of WT α-synuclein or an A53T mutant. Glucose deprivation,
the inhibition of glucose uptake, and the inhibition of the PPP were all observed to eliminate the
stimulatory effect of α-synuclein on paraquat toxicity (Figure 15). These results, in total, provide
strong evidence that glucose metabolism and signaling are critically involved in the toxic synergism
of paraquat exposure and the overexpression of α-synuclein. Specifically, α-synuclein potentiates
paraquat toxicity by impairing energy metabolism, glycolysis, and mitochondrial respiration.
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5. Conclusions
PD is currently believed to be a multifactorial disease, in which age, genetics, and environmental
toxins are all considered significant risk factors. The overexpression or mutation of α-synuclein [9,10]
has been identified as a major genetic factor associated with PD. In fact, the formation of α-synuclein
aggregates or Lewy bodies in dopaminergic neurons are the primary clinical sign of the disease.
Lewy bodies are correlated with neuronal loss and cognitive impairment, which are key symptoms of
PD. The biological function of α-synuclein is currently unknown, and while a variety of factors
have been shown to induce fibril formation, oxidative stress [49] is an important contributor.
Thus, mitochondrial dysfunction, energy failure, and redox imbalance induced by environmental
toxicants may be the primary mechanism leading to α-synuclein misfolding and aggregation in PD.
Exposure to environmental toxins, such as herbicides or pesticides, has been correlated with
an increase in the incidence of PD and has been shown to induce PD-like symptoms. Specifically,
environmental toxins have been shown to induce cell death of dopaminergic neurons primary through
an increase in ROS. Consequently, the loss of neurons in the substantia nigra of the idbrain is a
hallmark of PD. We have demonstrated that paraquat, rotenone, 6-OHDA, and MPP+ have distinct
molecul r me hanisms leading t dopaminergic neuron cell death. We have shown hat pa quat
hijacks the NADPH from the PPP to redox cycle, induces oxidative d mage, and impairs antioxi ant
defenses. Furthermore, paraquat increases gluc se transport and carb flux to the PPP (Figure 16).
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Finally, paraquat impairs the TCA cycle, which leads to the accumulation of citrate and impairment of
glycolysis. Critically, we have demonstrated a clear toxic synergy between paraquat and α-synuclein.
α-Synuclein impairs glycolysis and upregulates glucose transport. This channels carbon flux to the PPP
to increase paraquat’s redox cycling and ROS formation. In effect, α-synuclein feeds the production
of ROS that leads to its own misfolding and aggregation. Consequently, glucose metabolism plays
an important role in the molecular mechanism of PD since it regulates the effect of α-synuclein on
paraquat toxicity. The inhibition of glucose transporters prevents the potentiation of paraquat toxicity
by α-synuclein. Also, the inhibition of the PPP protects against this synergistic toxicity. Consistent
with the cell-based assays, we also observed that paraquat selectively induced metabolic dysfunction
in the midbrain and striatum of C57Bl/6 mice. Overall, glucose metabolism and AMPK contribute to
dopaminergic cell death, induced by PQ and α-synuclein interactions. Central carbon metabolism and
metabolic dysfunction/signaling are important contributors to dopaminergic cell death induced by
gene–environment interactions.
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Figure 16. Glucose metabolism and AMPK signaling regulate the toxicity of paraquat + α-synuclein.
We have demonstrated that PQ hijacks the PPP to use NADPH electrons for redox cycling and to
induce cell death. (a) We also revealed that glucose metabolism/transport contributes to PQ-induced
dopaminergic cell death, as evidenced by the protective effects of STF-31, AA (GLUT-like transport
inhibitors) and 2-DG (glucose metabolism inhibitor). (b) Furthermore, we present evidence that the
stimulation of glutamine metabolism via the TCA cycle by galactose supplementation also protects
against PQ; (c) in contrast, glucose metabolism protected against the mitochondrial complex I inhibitor
MPP+ while sole reliance on glutamine metabolism induced by galactose supplementation sensitized
cells to MPP+-induced cell death; (d) PQ-induced AMPK signaling is dependent on iNOS; (e) AMPK
signaling activated in response to PQ or glucose deprivation exerted a protective effect against PQ;
(f) overexpression of α-synuclein stimulated PQ toxicity (gene-environment interaction), metabolic
dysfunction and AMPK activation; (g) reproduced with permission from [98].
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6. Future Perspectives
The work presented herein provides some insights into potential underlying molecular
mechanisms that lead to PD, specifically with regards to the herbicide paraquat. It also provides
valuable evidence in support of a gene–environment interaction that may increase the likelihood of
developing PD. Nevertheless, the molecular mechanism attributed to other environmental toxins is still
currently unknown. Additionally, the biological role in PD for other genetic alterations (i.e., Parkin, DJ-1,
PINK1, and LRRK2) requires further investigation. Even in the case of α-synuclein, the mechanism
by which α-synuclein interacts with paraquat to induce cell death is still unclear. For example, it is
still uncertain if α-synuclein aggregates are a direct cause of neuronal cell death or if the formation of
Lewy bodies is a protective mechanism. Similarly, while some evidence was provided that cell-based
results are consistent with in vivo studies, substantial effort is still required to verify if any of these
processes are related to the development of PD in human patients. Consequently, there is more that
we still do not know about the molecular processes that lead to the development of PD. However, this
study clearly demonstrated the inherent value of combining metabolic studies with traditional cell
biology to explore the molecular mechanisms associated with Parkinson’s disease. Metabolomics is
expected to continue to play an important role in further PD studies.
While avoiding environmental toxins is obvious advice, it is particularly pertinent for individuals
with a genetic predisposition to developing PD. However, we are still far from identifying the
environmental agents that are a current concern to the public and are also linked to an increased
risk in developing PD. For example, most of the research to date has been focused on pesticides
(paraquat and rotenone) with a strong epidemiological association with PD, but whose usage is
restricted and thus are not currently a major risk for human populations. More importantly, it is
clear that a single environmental exposure will not (at least by itself) cause PD, which complicates
the further identification of gene–environment interactions, which, together with aging, may trigger
progressive neurodegeneration.
Since our research strongly suggests that glucose metabolism contributes to PQ toxicity and to
the synergistic effect between PQ and α-synuclein overexpression, a low-carbohydrate diet may be
beneficial to preventing the development and progression of PD [100]. In fact, a ketogenic diet (low
carbohydrate/high fat) has been reported to exert protective effects in PD [101]. To date, there are
no successful therapies to treat or prevent PD. As a result, α-synuclein has garnered a tremendous
amount of attention as a therapeutic target with a number of potential treatments in development or in
clinical trials [102]. These potential drugs are designed to increase α-synuclein clearance, prevent its
aggregation, or inhibit post-translational modifications, but no clinical successes have been observed
as of yet. Correspondingly, an alternative strategy may be to directly target the metabolic processes
“hijacked” by toxins associated with PD. FDA-approved metabolic inhibitors have been safely used
as drugs in humans for decades [103]. While broad-based antioxidant therapies have not had much
success in treating PD [104], a focused effort on developing drugs that inhibit a specific target of
a toxin, such as G6PD in the case of PQ, may be a viable alternative. Furthermore, a personalized
therapy based on a patient’s history of toxin exposure coupled with a ketogenic diet may prove to be a
successful approach to prevent the progression of the disease.
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Abbreviations
The following abbreviations are used in this manuscript:
1D one-dimensional
2D two-dimensional
3D three-dimensional
2-DG 2-deoxy-D-glucose
2-NBDG 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose
6-AN 6-aminonicotinamide
6-OHDA 6-hydroxydopamine
α-syn α-synuclein
AA ascorbic acid
ACO aconitase
AD Alzheimer’s disease
ADC aspartate 4-decarboxylase
AdEmpty empty adenovirus
AdG6PD adenovirus encoding for human G6PD
ADP adenosine diphosphate
ALDO fructose-bisphosphate aldolase
ALT Alanine transaminase
AMP adenosine monophosphate
AMPK AMP-activated protein kinase
AMPKα1 AMP-activated protein kinase α1
ANOVA analysis of variance
ATP adenosine triphosphate
BBB blood brain barrier
CS ATP-citrate synthase
CV-ANOVA ANOVA of the cross-validated residuals
DHAP dihydroxyacetone phosphate
DI-ESI-MS direct infusion-electrospray ionization mass spectrometry
DNA deoxyribonucleic acid
ECAR extracellular acidification rate
ECV extraction voltage
FBP fructose-1,6-bisphosphatase I
FUM fumarate hydratase
G6PD glucose-6-phosphate dehydrogenase
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GLDH Glutamate dehydrogenase
GLS Glutaminase
GLUT Na+-independent glucose transporters
GOT1 Aspartate aminotransferase, cytoplasmic
GPI Glucose-6-phosphate isomerase
GSH reduced glutathione
GSSH oxidized glutathione
HK hexokinase
HSQC heteronuclear single quantum coherence
IDH isocitrate dehydrogenase
iNOS inducible nitric oxide
LDH L-lactate dehydrogenase
LRRK2 leucine-rich repeat kinase 2
LSC succinyl-CoA synthetase
mBCl monochlorobimane
MB-PCA multiblock principal component analysis
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MB-PLS multiblock partial least squares
MDH malate dehydrogenase
Mn manganese
MOI multiplicity of infection
MPP+ 1-methyl-4-phenylpyridinium
MPTP 1-methyl-4-phenyl-1,2, 3, 6-tetrahydropyridine
MS mass spectrometry
NAC non-amyloid-β component of AD amyloid plaques
NADP nicotinamide adenine dinucleotide phosphate
NADPH nicotinamide adenine dinucleotide phosphate hydrogen
NG glucose free environment
NMR nuclear magnetic resonance spectroscopy
OCR oxygen consumption rate
OGDH 2-oxoglutarate dehydrogenase
OPLS orthogonal projection to latent structures
OXPHOS oxidative phosphorylation
pACC phosphorylated acetyl-CoA carboxylase
pAMPK phosphorylated AMP-activated protein kinase
PBS phosphate buffered saline
PC pyruvate carboxylase
PCA principal component analysis
PD Parkinson’s disease
PDH pyruvate dehydrogenase
PET positron emission tomography
PFK 6-phosphofructokinase 1
PGD 6-phosphogluconate dehydrogenase
PGK1 phosphoglycerate kinase 1
PGM phosphoglucomutase
PI propidium iodide
PINK1 phosphatase and tensin homolog (PTEN)-induced kinase 1
PLS partial least squares
PPP pentose phosphate pathway
PQ paraquat
PSC phase-scatter correction
RNA ribonucleic acid
ROS reactive oxygen species
RPI ribose 5-phosphate isomerase A
SCV sampling cone voltage
SDH succinate dehydrogenase
SE standard error
SGLT Na+-dependent glucose transporters
SNARE soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor
STF-31 4-[[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]methyl]-N-3-pyridinyl-benzamide
SUS shared and unique structures
TAL transaldolase
TCA tricarboxylic acid
TKT transketolase
TPI triosephosphate isomerase
US United States
UDP uridine diphosphate
UMP uridine monophosphate
WB Western blot
WT wild-type
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